PDMR Dealing Amendment

PDMR Dealing Amendment

 

The following amendment has been made to the ('PDMR Dealing') announcement released on 7 October 2022 at 12:28pm under RNS No 2105C

   

Amendments are identified with an asterisk (*).

 

Following this purchase Matthew Treagus holds 5,891 Ordinary Shares representing 0.006%* of the Company.

 

All other details remain unchanged.

 

The full amended text is shown below.

 

Oxford, UK - 7 October 2022 : Oxford Biomedica plc ("Oxford Biomedica" or the "Company") (LSE:OXB), a leading gene and cell therapy group, was informed that Matthew Treagus, Chief Information Officer, has purchased 1,390 ordinary shares of 50p each ("Ordinary Shares") in the Company on 7 October 2022 on the London Stock Exchange at a price of 355.6655p. Following this purchase Matthew Treagus holds 5,891 Ordinary Shares representing 0.006%* of the Company.

 

The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares purchased.

 

 

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")
a)	Name	Matthew Treagus
2.	Reason for the notification
a)	Position/status	Chief Information Officer
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Oxford Biomedica plc
b)	LEI code	213800S1GVQNXQ15K851
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument   Identification code	Ordinary Shares of 50 pence each     ISIN: GB00BDFBVT43
b)	Nature of the transaction	Purchase
c)	Price(s) and volumes(s)	Price(s) Volume(s) £3.556655 1,390
d)	Aggregated information · Aggregated volume · Aggregated total	1,390   £4,943.75
e)	Date of the transaction	07-10-2022
f)	Place of the transaction	London Stock Exchange, Main Market (XLON)

 

 

 

-Ends-

 

For further information, please contact:
Oxford Biomedica plc: Natalie Walter, Company Secretary	Tel: +44 (0)1865 783 000

 

 

About Oxford Biomedica

 

Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist focused on delivering life changing therapies to patients.

 

Oxford Biomedica plc and its subsidiaries (the Group) work across key viral vector delivery systems including those based on lentivirus, adeno-associated virus (AAV) and adenovirus, providing innovative solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development and manufacturing needs. Oxford Biomedica has built a sector leading lentiviral vector delivery system, LentiVector® platform, and is working on programmes from pre-clinical to commercial stage across a range of therapeutic areas with global partners.

 

Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In 2022, the Group established Oxford Biomedica Solutions, a US based subsidiary AAV manufacturing and innovation business, based near Boston, US.

 

Further information is available at www.oxb.com .